Latest Articles

  • Why 2026 Is the Year Clinical Trials Stop Drowning in Data

    Rich data sits across systems; actionable insight does not. Making clinical decisions on the back of mountains of collected data, without the systems to connect it all together, is like trying to understand the mood of a restaurant by looking at each patron individually. read more

  • From Data to Tissue

    The national-security regulatory landscape now layers a geopolitical framework onto the data flows, sample logistics, and vendor relationships that make modern clinical research possible. This architecture will not simplify. The DSP’s country-of-concern list may expand, the BIOSECURE Act’s designated-entities list will likely grow, and state legislatures continue adding requirements. read more

  • The Next Test for AI in Pharmacovigilance Is Trust, Not Accuracy

    An AI model can be right and still not be trusted. That’s what Bristol Myers Squibb (BMS) found six months into rolling out AI-powered adverse event processing: while F1 performance scores were tracking upward, the audit trail found reviewers still reopening cases the system had already cleared. read more

  • An Interview With Dave Miller, Ph.D.

    Early formulation decisions can make or break a program, yet they’re often made under significant data constraints. What are the most common mistakes sponsors make when they rush that decision, and what does it typically cost them downstream? read more